American Academy of Dermatology

AADA offers patient advocacy assistance with drug costsGetting involved with the AAD Association and state medical societies can help dermatologists stay informed and advocate more effectively for patients, experts say. Here's where to find help.
Don't undertreat margins of primary melanomaFollowing guidelines will help to ensure more consistent outcomes, expert says. Biopsy success rests less on the type of biopsy than the expertise of the physician. Read the recommendations.
Research advances yield new treatments for skin diseaseGenetic and pharmacogenomic breakthroughs have led to improved understanding of many diseases that affect the skin. How far we’ve come.
Moving toward personalized medicine for melanomaNew research indicates that cutaneous melanoma is the most mutation-driven form of all cancers. While research has determined that there is more than one form of cutaneous melanoma, forms with more mutations may respond better to immunotherapies that have been approved by the Federal Drug Administration (FDA) since 2011. Learn more
Risk Factors for Melanoma and Genetic TestingWhile one German study has shown that population-wide screening for melanoma could dramatically reduce mortality, potential problems with the strategy include cost due to the overall rarity of the disease, patient compliance, and difficulties identifying patients likely to develop melanoma. Therefore, scientists are developing prediction models to identify those at high risk for melanoma, which can include genetic factors. Learn more
AAD accepting awards/nominations for recognitionApplications and nominations for several awards are being accepted now for dermatologists to receive recognition for thier work during the upcoming American Academy of Dermatology annual meeting.
Practice gapsDermatologists often must weigh their desire for definitive data with the realities of caring for individual patients.
Rheumatology for the dermatologist
Rheumatology for the dermatologistThe signs and symptoms of some dermatologic and rheumatologic diseases sometimes overlap, and a better understanding of their associations and subsequent clinical and laboratory evaluations can help in optimizing the treatment and management of this patient population.
Drugs in Perspective: Otezla (apremilast)Otezla (apremilast), a small-molecule inhibitor of phosphodiesterase 4 (PDE4), was approved by FDA on March 21, 2014, for the treatment of adult patients with active psoriatic arthritis. On September 23, 2014, it was approved for a second indication, the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy
AADA questions GAO reportThe American Academy of Dermatology Association (AADA) and the Government Accountability Office (GAO) remain at odds over the GAO’s recommendation that Medicare payments limit financial incentives for self-referral of biopsies.